F&S Science

F&S Science is a journal of the American Society for Reproductive Medicine (ASRM) published by Elsevier, and it carries laboratory and translational work in reproductive medicine. It was founded in 2020, appears online only, prints four issues in a normal volume, and holds a 2025 Journal Impact Factor of 1.9.《F&S Science》是美国生殖医学学会（ASRM）的期刊，由 Elsevier 出版，刊载生殖医学的实验室与转化研究。该刊创办于 2020 年，仅在线上发行，常规一卷四期，2025 年影响因子为 1.9。

Fertility and Sterility, the society's clinical journal, publishes trials and practice guidance. This title takes the experiments behind them, from gamete biology to implantation, and asks authors to say what the finding means for human reproduction.该学会的临床期刊《Fertility and Sterility》发表试验与实践指南。本刊承接这些工作背后的实验，从配子生物学到着床，并要求作者说明研究结果对人类生殖意味着什么。

Scope

• The journal writes for reproductive biologists, embryologists and clinicians who want the mechanism behind a treatment rather than the protocol alone.该刊面向生殖生物学家、胚胎学家与临床医师，这些人要的是治疗背后的机制，而不只是操作方案。

• Sperm and oocyte biology supplies the largest single block of papers, with chromatin integrity, DNA fragmentation, the acrosome reaction and meiotic maturation all recurring subjects.精子与卵母细胞生物学构成最大的一类论文，染色质完整性、DNA 碎片化、顶体反应与减数分裂成熟都是反复出现的主题。

• Spermatogenesis is pursued in animal models as well, including rat and mouse studies of Leydig cell toxicity, varicocele and chemotherapy injury.精子发生也在动物模型中研究，包括大鼠与小鼠身上关于间质细胞毒性、精索静脉曲张与化疗损伤的工作。

• Preimplantation development and embryo culture attract a steady flow of submissions, among them proteomic comparisons of commercial single-step culture media and studies of trophectoderm biopsy.植入前发育与胚胎培养吸引稳定的来稿，其中包括对商品化一步法培养液的蛋白质组比较，以及滋养层活检研究。

• Time-lapse imaging and machine learning appear as instruments of embryo selection, with models that predict fertilisation or rank blastocysts for transfer.延时成像与机器学习作为胚胎筛选工具出现，相关模型可预测受精结果或对可供移植的囊胚排序。

• Implantation and the endometrium are treated at the level of receptors and signalling, for example forkhead box protein O1 and progesterone receptor expression at the time of embryo transfer.着床与子宫内膜的研究落在受体与信号层面，例如胚胎移植时叉头框蛋白 O1 与孕激素受体的表达。

• Ovarian biology covers folliculogenesis, granulosa cell responses to anti-Müllerian hormone, and the survival of cryopreserved ovarian tissue after grafting.卵巢生物学涵盖卵泡发生、颗粒细胞对苗勒管抑制物质的反应，以及冷冻保存的卵巢组织在移植后的存活。

• Reproductive endocrinology arrives by molecular routes, and polycystic ovary syndrome recurs in pathway studies and in network toxicology.生殖内分泌学以分子路径进入该刊，多囊卵巢综合征在通路研究与网络毒理学中反复出现。

• Genetics and epigenetics hold a firm place, from imprinted-locus methylation in oligospermic and azoospermic men to polygenic risk scoring in human embryos.遗传学与表观遗传学占有稳固位置，从少精与无精男性的印记位点甲基化，到人类胚胎的多基因风险评分。

• Environmental exposures are tested on reproductive tissue, with bisphenol A, microplastics and liquid crystal monomers among the substances examined.环境暴露在生殖组织上接受检验，双酚 A、微塑料与液晶单体都在被研究的物质之列。

• Diagnostic technology is assessed on tissue rather than described in the abstract, as when Raman spectroscopy is used to predict sperm retrieval in nonobstructive azoospermia.诊断技术要在组织上验证，而非停留在摘要描述，例如用拉曼光谱预测非梗阻性无精症患者能否取到精子。

• New subjects arrive quickly. Papers on SARS-CoV-2 receptor expression in gametes and embryos appeared within a year of the pandemic's start.新题目来得很快，关于新冠病毒受体在配子与胚胎中表达的论文在疫情开始一年内即已出现。

• The journal states that systematic reviews, meta-analyses, surveys and case reports fall outside its scope.该刊声明，系统综述、荟萃分析、问卷调查与病例报告不属于其收稿范围。

• Original reports fill most pages, and each volume also carries editorials, meeting summaries and the occasional historical essay.原创论文占据多数篇幅，每卷还刊载社论、会议纪要，偶尔也有史学随笔。

• Much of the work uses human tissue, gametes or embryos, and animal models appear where human material cannot answer the question.相当一部分工作使用人体组织、配子或胚胎，动物模型出现在人体材料无法回答问题时。

• Because the subject is fixed and the methods are not, one issue can move from mass spectrometry to a clinical prediction model without leaving the scope.由于主题固定而方法不限，同一期可以从质谱分析走到临床预测模型，而不越出收稿范围。

History

• The first issue is dated August 2020 and opens with an editorial headed From the Editor-in-Chief.第 1 卷第 1 期标注 2020 年 8 月，开篇是一篇题为 From the Editor-in-Chief 的社论。

• Volume 1 carried two issues, and from volume 2 in 2021 the journal settled into four issues a year.第 1 卷只有两期，自 2021 年第 2 卷起，该刊稳定为每年四期。

• Volumes 3 to 6 kept that rhythm, and volume 7, dated 2026, has already reached its fifth issue.第 3 卷至第 6 卷保持这一节奏，标注 2026 年的第 7 卷已经出到第 5 期。

• MEDLINE and PubMed indexed the title from the first issue, which is a fast start for a new journal.MEDLINE 与 PubMed 从第 1 卷第 1 期起即收录该刊，对新刊而言起步很快。

• There is no print ISSN. The journal is identified by the electronic number 2666-335X and is distributed through ScienceDirect.该刊没有印刷版 ISSN，以电子号 2666-335X 识别，并通过 ScienceDirect 发行。

• The 2025 Journal Citation Reports give an Impact Factor of 1.9 and a five-year figure of 1.8.2025 年期刊引证报告给出影响因子 1.9，五年影响因子 1.8。

• The title sits in two ESCI categories, Obstetrics and Gynecology at Q3 with a rank of 84 out of 143, and Reproductive Biology at Q4 with 34 out of 44.该刊列入两个 ESCI 类目，妇产科学为 Q3，在 143 种期刊中排第 84 位，生殖生物学为 Q4，在 44 种中排第 34 位。

• JCR counts about 45 articles a year and 360 citations, with a cited half-life of three years.JCR 统计其年发文约 45 篇，总被引 360 次，被引半衰期为三年。

• The Impact Factor moved from 1.5 in 2024 to 1.9 in 2025, the first clear rise since the title received a rating.影响因子从 2024 年的 1.5 升至 2025 年的 1.9，这是该刊获得评级以来的首次明显上升。

• A fifth issue appeared in volume 7, dated September 2026, one more than the four issues of volume 6.第 7 卷多出一期，标注 2026 年 9 月，比第 6 卷的四期多出一期。

• The early volumes already mixed laboratory reports with history, as in a personal account of the development of human gonadotropins by Robert W. Rebar.早期各卷已把实验报告与史学文章混排，例如 Robert W. Rebar 关于人促性腺激素发展史的个人叙述。

• Since 2021 the journal has named Reviewers of the Year in an annual editorial, and the practice continued with the 2025-2026 list.自 2021 年起，该刊每年以社论形式公布年度审稿人，2025 至 2026 年度的名单延续了这一做法。

• Editorials from the editor-in-chief run through the volume years, with signed pieces in 2022, 2023, 2024 and 2025.主编社论贯穿各卷年份，2022 年、2023 年、2024 年与 2025 年均有署名文章。

Editors

• William H. Catherino is editor-in-chief and has held the post since the launch, when he wrote the opening editorial of volume 1.（William H. Catherino）担任主编，自创刊起即任此职，第 1 卷的开篇社论出自他手。

• He is a professor in the Department of Gynecologic Surgery and Obstetrics at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.他是马里兰州贝塞斯达市美国军医大学妇外科与产科系的教授。

• His own laboratory studies uterine leiomyoma, including the extracellular matrix of fibroids and the response of that tissue to a gonadotropin-releasing hormone antagonist.他本人的实验室研究子宫平滑肌瘤，包括肌瘤的细胞外基质与促性腺激素释放激素拮抗剂对该组织的作用。

• His editorials recur in every volume, which makes a single editorial voice a fixed feature of the journal.他的社论在各卷反复出现，使单一的主编声音成为该刊的固定特征。

• The annual Reviewers of the Year editorial thanks the referees whom the editors judged outstanding.一年一度的年度审稿人社论，向编辑们认为表现突出的审稿人致谢。

• Submissions are read by external referees, and the publisher's editorial office works from the New York address recorded in the NLM catalogue.来稿由外部审稿人评阅，编辑部的办公地址是 NLM 目录所记的纽约。

• The journal belongs to ASRM, which lists it with Fertility and Sterility, F&S Reports and F&S Reviews as its four titles.该刊属于 ASRM，该学会把它与《Fertility and Sterility》、《F&S Reports》和《F&S Reviews》并列为旗下四种期刊。

• Within that group this title is the one given to laboratory work, while Fertility and Sterility carries the clinical journal.在这一组刊物中，本刊承担实验室工作，而《Fertility and Sterility》承担临床部分。

• Editorials are indexed as ordinary articles, so they carry DOIs and can be cited like research papers.社论按普通文章索引，因此带有 DOI，可以像研究论文一样被引用。

• His pieces appear at intervals of a few months, with signed editorials in April and October 2025 marking volume 6 issues 2 and 4.他的文章每隔数月出现一次，2025 年 4 月与 10 月的署名社论分别对应第 6 卷第 2 期与第 4 期。